A GPR18-based signalling system regulates IOP in murine eye

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 834-843

  Caldwell, Meggie D ^a   Hu, Sherry Shu Jung ^d   Viswanathan, Suresh ^c   Bradshaw, Heather ^c   Kelly, Melanie E M ^a,b   Straiker, Alex ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c INDIANA UNIVERSITY   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

cannabinoid; eye; GPR18; intraocular pressure; mouse; THC

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 18; G PROTEIN COUPLED RECEPTOR 55; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CILIARY BODY EPITHELIUM; CONTROLLED STUDY; CORNEA EPITHELIUM; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRABECULAR MESHWORK;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTERIOR EYE SEGMENT; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CILIARY BODY; ENDOCANNABINOIDS; EPITHELIUM, CORNEAL; EYE PROTEINS; GLYCINE; INTRAOCULAR PRESSURE; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS; SIGNAL TRANSDUCTION;

EID: 84878314235     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12136     Document Type: Article

References (40)

1. Bisogno T, Delton-Vandenbroucke I, Milone A, Lagarde M, Di Marzo V, (1999). Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys 370: 300-307.
2. Bradshaw HB, Rimmerman N, Krey JF, Walker JM, (2006). Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291: R349-358.
3. Bradshaw HB, Rimmerman N, Hu SS, Benton VM, Stuart JM, Masuda K, et al. (2009). The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem 10: 14.
4. Calignano A, La Rana G, Giuffrida A, Piomelli D, (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
5. Cervino A, (2006). Rebound tonometry: new opportunities and limitations of non-invasive determination of intraocular pressure. Br J Ophthalmol 90: 1444-1446.
6. Chen J, Matias I, Dinh T, Lu T, Venezia S, Nieves A, et al. (2005). Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun 330: 1062-1067.
7. Crandall J, Matragoon S, Khalifa YM, Borlongan C, Tsai NT, Caldwell RB, et al. (2007). Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthal Res 39: 69-75.
8. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98: 9371-9376.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
10. Gastinger MJ, Singh RS, Barber A, (2006). Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47: 3143-3150.
11. Hepler RS, Frank IR, (1971). Marihuana smoking and intraocular pressure. JAMA 217: 1392.
12. Hu SS, Arnold A, Hutchens JM, Radicke J, Cravatt BF, Wager-Miller J, et al. (2010). Architecture of cannabinoid signaling in mouse retina. J Comp Neurol 518: 3848-3866.
13. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, et al. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276: 42639-42644.
14. Hudson BD, Beazley M, Szczesniak AM, Straiker A, Kelly ME, (2011). Indirect sympatholytic actions at beta-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists. J Pharmacol Exp Ther 339: 757-767.
15. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
16. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M, (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
18. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, et al. (2006). Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun 347: 827-832.
19. Lauffer LM, Iakoubov R, Brubaker PL, (2009). GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58: 1058-1066.
20. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
22. McHugh D, Page J, Dunn E, Bradshaw HB, (2012a). Delta(9) -THC and N-arachidonyl glycine are full agonists at GPR18 and cause migration in the human endometrial cell line, HEC-1B. Br J Pharmacol 165: 2414-2424.
23. McHugh D, Page J, Dunn E, Bradshaw HB, (2012b). Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165: 2414-2424.
24. McHugh D, Wager-Miller J, Page J, Bradshaw HB, (2012c). siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration. J Mol Signal 7: 10.
25. Mackie K, Stella N, (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298-E306.
26. Matsuda S, Kanemitsu N, Nakamura A, Mimura Y, Ueda N, Kurahashi Y, et al. (1997). Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res 64: 707-711.
27. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, et al. (2008). Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283: 21054-21064.
28. Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T, (1998). Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci 63: 2181-2188.
29. Pertwee RG, (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17: 1360-1381.
30. Porcella A, Casellas P, Gessa GL, Pani L, (1998). Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol Brain Res 58: 240-245.
31. Porcella A, Maxia C, Gessa GL, Pani L, (2000). The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci 12: 1123-1127.
32. Quigley HA, Broman AT, (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90: 262-267.
33. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227-230.
34. Stella N, Schweitzer P, Piomelli D, (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778.
35. Straiker A, Sullivan JM, (2003). Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander. J Neurophysiol 89: 2647-2654.
36. Straiker A, Stella N, Piomelli D, Mackie K, Karten HJ, Maguire G, (1999a). Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc Natl Acad Sci U S A 96: 14565-14570.
37. Straiker AJ, Maguire G, Mackie K, Lindsey J, (1999b). Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 40: 2442-2448.
38. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N, (2005). Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280: 11082-11092.
39. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.
40. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, et al. (2009). Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 284: 17304-17319.